Myeloid Therapeutics has rebranded as CREATE Medicines, announcing this strategic shift on October 6, 2025. The company is now focused on transforming immunotherapy through RNA-based in vivo multi-immune programming. CREATE Medicines is pioneering a proprietary mRNA-LNP platform that directly programs immune cells inside the body, enabling scalable, repeat-dose, off-the-shelf immunotherapies. This approach expands beyond myeloid cells to include T cells and NK cells, aiming to deliver therapies with greater clinical impact.

Key upcoming milestones include the initiation of the first patient dosing for MT-304 (HER2; solid tumors) in Q4 2025, which features a first-in-class multi-immune CAR engaging NK and myeloid cells. The company is also advancing ongoing studies of MT-302, MT-303, and its retrotransposon-based CAR-T platform, as well as additional multi-lineage programs in preclinical developmentprnewswire.com+3.

Would you like more details on their technology platform or clinical programs?

Directly programming immune cells inside the body using mRNA-LNP (lipid nanoparticle) technology presents several potential risks and challenges:

1. Off-Target Effects and Poor Transfection: Current mRNA-LNP formulations can accumulate in unintended organs (such as the liver) rather than targeting immune cells in secondary lymphoid organs. This nonspecific accumulation limits the effectiveness of the therapy and may cause unwanted side effectsbiorxiv.org+1.

2. Immunogenicity and Inflammatory Responses: mRNA-LNPs can trigger innate immune responses through pathways like Toll-like receptors (TLRs), MDA5, and NLRP3, leading to the production of proinflammatory cytokines (e.g., IFN-γ, IL-1β, IL-6). While some immune activation is desired, excessive or uncontrolled responses can be harmful, causing inflammation or autoimmune-like reactionsbiorxiv.org+2.

3. Stability and Handling Issues: Mechanical stress during handling, transport, or storage can damage LNPs, reducing their stability and effectiveness. This requires optimized conditions to maintain the integrity of the formulationphosphorex.com.

4. Long-Term Safety and Repeated Administration: Although mRNA does not integrate into the genome, repeated administration may still pose risks related to chronic immune activation or unknown long-term effects, especially in vulnerable populations such as pregnant or lactating womenfrontiersin.org.

5. Manufacturing and Distribution Challenges: Scaling up production, ensuring consistent quality, and addressing global distribution logistics remain significant hurdles for widespread clinical usepmc.ncbi.nlm.nih.gov.

6. Vaccine Hesitancy and Public Perception: Misinformation and concerns about safety, efficacy, and long-term impacts can hinder acceptance and uptake of mRNA-based therapiesglobenewswire.com.

These challenges highlight the need for ongoing research to improve targeting, reduce off-target effects, and ensure the safety and efficacy of in vivo immune programming technologies.

Would you like more details on any specific risk or how these challenges are being addressed?